Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device takes on tough Barrett's esophagus cases

NCT ID NCT03364114

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a device called EndoRotor to remove abnormal cells in people with Barrett's esophagus that didn't improve after standard treatments. The device cuts and removes tissue through a scope. Only 15 people took part, and the study was stopped early, so we don't have clear answers on how well it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EndoRotor Mucosal Resection System (a device that cuts and removes tissue through an endoscope)
What this could lead to
If successful, this could offer a new way to remove precancerous cells in Barrett's esophagus when standard treatments fail or cause too much pain.
What could go wrong
The trial was terminated early with only 15 participants, so results are very limited. It is unclear if the device is better or safer than continued ablation therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Feb 2018

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects who are greater than 30 and less than 90 years of age; inclusive of males and females. 2. Subjects with confirmed Barrett's esophagus with dysplasia (low-grade or high-grade) and meeting at least one of the following criteria: 1. Failed 3 ablative procedures (RFA and/or Cryotherapy). 2. Failed at least 1 ablative procedure (RFA and/or Cryotherapy) and are intolerant to the procedure due to pain, where intolerant is defined as post-procedure dysphagia or odynophagia persisting for 24 hours or greater or requiring narcotic analgesia for a duration of more than 24 hours. 3. Residual Barrett's length is ≥1 cm and ≤6 cm. 4. No confirmed evidence of esophageal adenocarcinoma (EAC) at the time of therapy. 5. Subject capable of giving informed consent. 6. Subject has a reasonable expectation for prolonged survival (greater than 2 years). 7. Subject can tolerate repeated endoscopic procedures. 8. Absence of strictures refractory to dilation that preclude the passage of the endoscope 9. Patients who were on acid suppression therapy (i.e. PPIs) during the course of failed primary ablative therapy, and who can continue acid suppression therapy for the entire time they are on the clinical study. 10. Subjects with the ability to understand the requirements of the study, who have provided written informed consent, and who are willing and able to return for the required follow-up assessments through 12 months, as indicated. Exclusion Criteria: 1. Subject unable to give informed consent. 2. Subject is unwilling to return for repeated endoscopies. 3. Confirmed endoscopic and or histologic evidence of EAC at time of therapy. 4. Residual Barrett's longer than 6 cm. 5. Subjects with nodular Barrett's esophagus. 6. Subjects who are on anticoagulant therapy that cannot be discontinued for 5 days before and after the procedure. 7. Subjects with known coagulopathy defined as abnormal prothrombin or partial thromboplastin time. 8. History of esophageal varices 9. LA Grade B, C, or D esophagitis. 10. Esophageal stricture refractory to dilation preventing passage of endoscope or catheter. 11. Any previous esophageal surgery, except fundoplication without complications. 12. Medically uncorrectable hypotension or hypertension. 13. Any condition that in the opinion of the investigator would create an unsafe clinical situation that would not allow the patient to safely undergo an endoscopic procedure (lack of medical clearance). 14. Pregnant or lactating women or women of childbearing potential who do not employ a reliable method of contraception as judged by the Investigator, and/or are not willing to use reliable contraception for the duration of study participation. 15. Subject has known severe psychiatric disorder, substance abuse, or other reason for being unable to follow trial follow-up instructions. 16. Patient has a known significant concomitant illness with a life expectancy of less than 2 years. 17. Subject is known to be currently enrolled in another investigational trial that could interfere with the endpoint analyses of this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Barrett's esophagus with dysplasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NHS University College Hospital

    London, United Kingdom

  • Sahlgrenska University Hospital

    Gothenburg, 413 45, Sweden

  • The Mayo Clinic

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.